Status:
COMPLETED
Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Prostatic Hyperplasia
Eligibility:
MALE
21+ years
Brief Summary
Study to describe Tamsulosin prescription characteristics in a representative population of patients on treatment for benign prostatic hyperplasia
Eligibility Criteria
Inclusion
- Patients older than 21 years old diagnosed with benign prostatic hyperplasia (BPH), who require pharmacological treatment to relieve symptoms and improve their quality of life, according to physician's judgment. The study will include naïve patients and patients not responding to previous therapy who receive Secotex as alternative or complementary treatment. The decision to treat a patient with Tamsulosin must be based on the best standard accepted in the clinical practice and must be carried out following Secotex (Tamsulosin) prescription information
Exclusion
- Patients with known hypersensitivity to Tamsulosin or any of its ingredients, history of orthostatic hypotension or severe liver failure, or with any missing data required to complete the questionnaire are excluded
Key Trial Info
Start Date :
April 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1060 Patients enrolled
Trial Details
Trial ID
NCT02245555
Start Date
April 1 2006
Last Update
September 19 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.